antibody-drug conjugate
Alentis Therapeutics Raises $181.4M in Series D Financing
The firm plans to put the funds toward advancing its CLDN-1-directed antibody-drug conjugates, ALE.P02 and ALE.P03, into the clinic.
AstraZeneca, Daiichi Sankyo Hoping to Sway FDA of Dato-DXd Benefit Despite Overall Survival Miss
Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.
Merck, Daiichi Sankyo to Discuss Antibody-Drug Conjugate Data in EFGR-Mutated NSCLC With Regulators
The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.
TORL BioTherapeutics' CLDN6-Targeting Antibody-Drug Conjugate Demonstrates Encouraging Early Results
Premium
Phase I data presented at ESMO suggested that TORL-1-23 may have particularly strong activity in CLDN-positive advanced ovarian cancer.
I-SPY 2.2 Study IDs Early Breast Cancer Patients Who Benefit From Pre-Surgery Dato-DXd, Imfinzi
Premium
The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape future Phase III clinical trials.
Jul 11, 2024
Myricx Bio Raises £90M in Series A Financing
Mar 14, 2024
Tubulis Raises $139M in Series B2 Funding
Oct 25, 2023